Lytix Biopharma (LYTIX) Q3 2024 earnings summary

Executive summary

• Achieved significant positive Phase II results for LTX-315 in basal cell carcinoma, with 86% tumor reduction and 51% complete clearance, and strong efficacy in late-stage melanoma, including 40% disease control and durable partial responses.

• Progressed LTX-315 in three ongoing Phase II studies, including the NeoLIPA study in early-stage melanoma, with the first patient treated and interim results expected in 2025.

• Advanced LTX-401 with a new superior formulation, showing improved anticancer effects, extended patent life, and regulatory engagement planned.

• Strategic partnership with Verrica Pharmaceuticals validated by milestone payments and royalties, with a licensing agreement potentially yielding over $110 million and 10–mid-10% royalties.

• Presented positive BCC Phase II results at major conferences and appointed a new CEO at Verrica to support LTX-315 advancement.

Financial highlights

• Cash and short-term financial investments at period end totaled NOK 43.5 million, supporting a runway into Q2 2025.

• Raised NOK 50 million in a recent share offering, primarily from existing shareholders.

• Q3 2024 operating income was NOK 231k, mainly from LTX-315 stability testing; operating expenses rose to NOK 23.3 million due to increased R&D.

• Loss from operations was NOK 23.0 million in Q3 2024, with a YTD 2024 loss of NOK 62.4 million.

• Cost efficiency measures and site closures implemented to streamline expenses.

Outlook and guidance

• Focus on securing milestone payments and royalties through partnerships and late-stage development.

• Upcoming milestones include BCC clinical study report (Q4 2024), immune response analysis (Q1 2025), FDA End of Phase 2 meeting (H1 2025), and interim NeoLIPA results (2025).

• Regulatory meeting for LTX-401 scheduled for Q4 2024; ATLAS-IT-05 finalization expected H2 2025.

• Confident in improved patient response in early-stage melanoma due to stronger immune profiles.

• Plans to approach larger pharmaceutical partners with positive interim data.